Initial evidence-based findings of three-year study strongly supports MiYOSMART portfolio 

HOYA Vision Care, committed to developing innovative  solutions to address the growing problem of myopia progression in children, extended its  research to Europe in an effort to battle this global problem.  

In the eye care industry, most research on childhood myopia is being conducted in East Asia,  where the condition is most prevalent.1 With myopia increasing worldwide, there is a need to  test the effectiveness of myopia management solutions in children of other ethnicities and  geographic areas.1 To gather the needed data, the HOYA Global Medical Affairs team began  conducting a three-year observational study in the United Kingdom (UK), with the goal of  extending MiYOSMART benefits to European children with myopia. The study reached its one year milestone earlier this year, with the results officially presented at the Association for  Research in Vision and Ophthalmology (ARVO) 2023 Conference held 23-27 April, in New  Orleans.2 

The study involves 128 children aged 5 to 15 recruited at three university centres in the UK. All  children were prescribed MiYOSMART spectacle lenses and their progress was followed, with  the aim to evaluate the performance of MiYOSMART spectacle lenses in European children.2 T  

The results from this study demonstrated similar effectiveness of MiYOSMART spectacle lenses  between European and Asian children, particularly in children aged 8 to 13 years .2, 3 Most  children were symptom-free within one week, showing strong tolerability and acceptance.2 

“Childhood myopia is a widespread global concern, and our unwavering commitment to fighting  this issue through innovative solutions like MiYOSMART spectacle lenses is stronger than ever. The interim results of our European research are encouraging,” said Dr Natalia Vlasak, Global  Head of Medical and Scientific Affairs at HOYA Vision Care. “The comparable outcomes in the  

European cohort underscore that MiYOSMART represents an effective approach to slowing myopia progression in children, irrespective of their ethnicity. We look forward to sharing the results of this three-year study in the near future.”

Over 2 million parents across the world have already trusted MiYOSMART, since its launch in  2018.4 With the MiYOSMART evidence extending to European cohort, HOYA Vision Care will  continue to help fight and control the growing problem of myopia around the world.  

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the  management of Myopia in all countries, including the U.S., and are not currently available for sale  in all countries, including the U.S. 

About HOYA Vision Care 

For over 60 years, HOYA Vision Care has been a passionate and global leader in optical  technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses,  HOYA continuously aims to bring the best possible vision care solutions to Eye Care  Professionals and their patients around the world. The company supplies lenses in 110  countries with a network of over 17,000 employees and 43 laboratories around the globe. 

# # # 


  1. Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia  in school children worldwide. BMC Ophthalmol. 2020;20(1):27. 
  2. McCullough S, Barr, H, Fulton, J, et al. 2-Year Multi-Site Observational Study of MiYOSMART  myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023; 23-27 April 2023;  New Orleans, LA, USA. 
  3. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated  Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.  Br J Ophthalmol. 2020;104(3):363-8. 
  4. Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of July  2023. 

For further information please contact: 

HOYA Vision Care PR  

Name: Susan Brown  


Follow HOYA Vision Care on Linkedin